MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q3
hinzugefügt 10.11.2025
Celldex Therapeutics Betriebsaufwand 2011-2026 | CLDX
Betriebsaufwand Jährlich Celldex Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 58.1 M | 85.9 M | 122 M | 140 M | 135 M | 126 M | 83.2 M | 58.5 M | 43.6 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 140 M | 43.6 M | 94.7 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K |  USA |
 |
Biogen
BIIB
|
5.39 B | $ 172.45 | 0.5 % | $ 25.1 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.97 | 0.81 % | $ 5.29 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.65 | 2.82 % | $ 8.78 B |  Australia |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 117.57 | 1.37 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
BioXcel Therapeutics
BTAI
|
107 M | $ 1.79 | -1.64 % | $ 4.54 M | USA |
 |
BioLineRx Ltd.
BLRX
|
28.1 M | $ 2.94 | -5.16 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Catalyst Biosciences
CBIO
|
176 M | $ 12.13 | -5.23 % | $ 799 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 233.71 | -0.71 % | $ 5 B |  Danmark |
 |
Burford Capital Limited
BUR
|
106 M | $ 9.81 | 0.56 % | $ 1.57 B | Britain |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
731 M | $ 67.35 | 0.45 % | $ 9.01 B | USA |
 |
Compugen Ltd.
CGEN
|
40.4 M | $ 2.06 | -1.67 % | $ 184 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 4.43 | -0.78 % | $ 9.64 B | Israel |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Cellectis S.A.
CLLS
|
109 M | $ 4.16 | -6.94 % | $ 116 M |  France |
 |
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
168 M | $ 25.89 | -0.14 % | $ 1.25 B | USA |
 |
Coherus BioSciences
CHRS
|
231 M | $ 2.28 | 10.68 % | $ 215 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
539 M | $ 13.48 | 0.67 % | $ 4.17 B | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Aptose Biosciences
APTO
|
26.3 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.74 | 1.48 % | $ 17.2 M | USA |
 |
AstraZeneca PLC
AZN
|
17.6 B | $ 94.2 | 1.34 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | USA |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |